Product Description
[Veterinary Drug Name]
Generic Name: Spectinomycin Hydrochloride and Lincomycin Hydrochloride Soluble Powder
[Composition] Spectinomycin Hydrochloride, Lincomycin Hydrochloride
[Character] This product is a white or off-white powder.
[Pharmacological Action]
Pharmacodynamics: Spectinomycin is an aminoglycoside antibiotic that has a moderate inhibitory effect on various Gram-negative bacilli, such as Escherichia coli, Salmonella spp., Shigella spp., and Proteus spp. It is also sensitive to streptococci, pneumococci, Staphylococcus epidermidis, and certain mycoplasmas (e.g., Mycoplasma gallisepticum, Mycoplasma meleagridis, Mycoplasma synoviae, etc.). It is generally not sensitive to Streptococcus viridans and Staphylococcus aureus. It is usually resistant to Pseudomonas aeruginosa and spirochetes. Intestinal bacteria have a relatively widespread resistance to spectinomycin, but cross-resistance with streptomycin is not observed. Lincomycin has good antibacterial activity against anaerobic bacteria, such as Fusobacterium spp., Peptococcus spp., Peptostreptococcus spp., Clostridium tetani, Clostridium perfringens, and most Actinomyces spp. Lincomycin primarily acts on the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and thereby affecting protein synthesis.
Pharmacokinetics: After oral administration, spectinomycin is absorbed only at a rate of 7%, but it maintains a high concentration in the gastrointestinal tract. The tissue concentration of the drug is lower than the serum concentration. It does not easily enter cerebrospinal fluid or the eye, and its plasma protein binding rate is not high. Most of the drug is excreted unchanged via glomerular filtration. Lincomycin has poor oral absorption, with a bioavailability of 30%–40%. Feeding administration can reduce its absorption rate and amount. When chickens are administered this product at a dose of 50 mg per kilogram of body weight (dissolved in drinking water) for 7 consecutive days, the plasma concentration of Lincomycin reaches 0.14 μg/ml during the trial period, while the concentration of spectinomycin is extremely low, only exceeding 0.1 μg/ml after 7 days.
[Drug Interactions]
1. Combined use with Lincomycin can significantly enhance the antibacterial activity against mycoplasmas and broaden the antimicrobial spectrum.
2. Lincomycin can reduce the efficacy when used with anticholinesterase drugs.
3. Antagonistic effects are observed when used with erythromycin.
[Indications]
Antibiotic. Used for infections caused by Gram-negative bacteria, Gram-positive bacteria, and mycoplasmas.
[Administration and Dosage] Based on this product. For oral administration via drinking water: For chicks aged 5–7 days, 0.5–0.8 g per 1 L of water, for 3–5 consecutive days.
[Adverse Reactions] No adverse reactions have been observed when used at the recommended dosage.
[Precautions] For use in chicks aged 5–7 days only.
[Withdrawal Period] Not required.
[Specifications] 100 g: Spectinomycin 40 g (40 million units) and Lincomycin 20 g (calculated as C18H34N2O6S)
[Packaging] 10 g/bottle × 60 bottles/carton; 500 g/bag × 20 bags/carton; 1,000 g/bag × 10 bags/carton
[Storage] Store in a tightly closed container and keep in a dry place.
[Shelf Life] 2 years.
[Manufacturer] Qingdao KDN Animal Pharmaceutical Co., Ltd.
Manufacturing Address: No. 85 Keyun Road, High-Tech Zone, Qingdao
Postal Code: 266000
Tel: 0532-87905398
Fax: 0532-87905229
To be used only under veterinary supervision
